Tag:

Pfizer

Latest Headlines

Latest Headlines

Pfizer prevails in first court test of Zoloft birth-defect claims

Pfizer racked up an important win in the first trial over Zoloft's alleged links to birth defects. A St. Louis jury decided on Friday that the drug giant isn't liable for congenital abnormalities in a boy whose mother took Zoloft during her pregnancy.

Gilead's hep C drugs make it king of the hill in U.S. drug sales

The U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences, whose hep C drugs vaulted it to the top, according to  PMLiVE  based on sales info from GlobalData.

Pfizer's palbociclib impresses in PhIII breast cancer study

Pfizer reported today that it had cut short a Phase III study of palbociclib, recently approved under an accelerated pathway as Ibrance, after clearly demonstrating that it had met its primary endpoint: progression-free survival with a combination of Ibrance plus fulvestrant in women with hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer.

Pfizer's Ibrance shines in latest breast cancer study

Pfizer won accelerated approval of Ibrance as a first-line breast cancer treatment in February. Now it says that data in a study of the drug as a second-line treatment was so good that it stopped that study early.

Tech it out: Pfizer, AARP and UnitedHealthcare push innovation

It's no secret that technology is transforming healthcare. But Big Pharma? Not quite yet. Some risk-averse drugmakers have been slow to adopt the digital lifestyle.

Japan's RegImmune joins with Pfizer on Type 1 diabetes antigen candidate

Japan's RegImmune has joined with Pfizer and the former Juvenile Diabetes Research Foundation in a partnership to collaborate on research for an antigen-specific preventative for Type 1 diabetes. Financial arrangements were not disclosed, but Pfizer is to provide finances and expertise.

The coming generics threat to Pfizer's Viagra brand just got scarier

The glory days for Pfizer's Viagra are winding down in the U.S., and now, another generics company has the go-ahead to help pave the way for the drug's demise.

J&J to use drug delivery device for HBV vaccine thanks to $85M partnership

J&J's Janssen Pharmaceuticals just announced a partnership involving the use of Ichor Medical Systems' TriGrid electroporation technology to deliver a DNA vaccine for hepatitis B.

IDT Australia release on FDA nod for 23 generics begs the question: Where's the beef?

Australia Stock Exchange-listed IDT Australia has issued another in a series of announcements about acquiring 23 generic drugs marketed in the United States, the latest release stating the U.S. FDA has noted the transfer of ownership to IDT.

Zoloft lawyers accuse Pfizer of hiding birth-defect risks

Pfizer researchers found evidence last year that pregnant women using its Zoloft antidepressant had a higher risk of giving birth to a child with heart problems and other congenital anomalies, Bloomberg reports. Now, the internal report has surfaced in a lawsuit blaming Zoloft for a young boy's heart defect, the first such case to go to trial.